<DOC>
	<DOC>NCT01225081</DOC>
	<brief_summary>This study is to evaluate the efficacy and safety after concomitant administration of ASP1941 and pioglitazone in patients with diabetes mellitus.</brief_summary>
	<brief_title>A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Pioglitazone in Type 2 Diabetic Patients</brief_title>
	<detailed_description>This study is to evaluate the efficacy (HbA1c change from baseline) and safety of ASP1941 in combination with pioglitazone in subjects with type 2 diabetes mellitus (T2DM) who have inadequate glycemic control with pioglitazone alone. The effects of ASP1941 are compared with those of placebo. Double blind period continues for 24 weeks followed by open period in each patient.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Type 2 diabetic patients receiving pioglitazone monotherapy for at least 4 weeks HbA1c value between 7.0 and 9.5% Body Mass Index (BMI) 20.0 45.0 kg/m2 Type 1 diabetes mellitus patients Serum creatinine &gt; upper limit of normal Proteinuria (albumin/creatinine ratio &gt; 300mg/g) Dysuria and/or urinary tract infection, genital infection Significant renal, hepatic or cardiovascular diseases Severe gastrointestinal diseases Heart failure patients</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>ASP1941</keyword>
	<keyword>Diabetes mellitus</keyword>
	<keyword>pioglitazone</keyword>
</DOC>